Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study

Takashi Kadowaki,Masakazu Haneda,Nobuya Inagaki,Yasuo Terauchi,Atsushi Taniguchi,Kazuki Koiwai,Henning Rattunde,Hans J. Woerle,Uli C. Broedl

Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study

2015

Takashi Kadowaki
Masakazu Haneda
Nobuya Inagaki
Yasuo Terauchi
Atsushi Taniguchi
Kazuki Koiwai
Henning Rattunde
Hans J. Woerle
Uli C. Broedl

Introduction The aim of this randomized, double-blind, parallel-group study was to investigate the safety and efficacy of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes (T2DM).

Keywords:

Diabetes mellitus
Type 2 diabetes
Empagliflozin
Medicine
pharmacology toxicology
group study
double blind
Rheumatology
Anesthesia
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations